Updated:
LumiThera
LumiThera developed Valeda, the first FDA-authorized photobiomodulation treatment for dry AMD, commercialized through Alcon.
LumiThera
LumiThera developed the Valeda Light Delivery System, a noninvasive device that treats dry age-related macular degeneration (AMD) using photobiomodulation. The company gained FDA authorization in 2024 for Valeda to improve visual acuity in patients with early or intermediate dry AMD who have not yet developed central geographic atrophy. LumiThera's technology is distributed globally through Alcon, the eye care division of Novartis. Valeda applies three wavelengths of light — 590 nm, 660 nm, and 850 nm — to stimulate mitochondrial energy production in retinal cells, counteracting the mitochondrial dysfunction implicated in dry AMD. The LIGHTSITE III pivotal trial showed that 84% of treated patients maintained or improved vision at about two years, with more than 60% gaining at least one line of visual acuity (per the LIGHTSITE III study, 2024). The company has not disclosed a portfolio of investments or asset-class allocation; its single product is Valeda. LumiThera operates from Poulsbo, Washington, with a registered presence in Tokyo, Japan. The company does not disclose its team size, funding history, or ownership structure. There are no publicly named principals, advisors, or investors. The firm has not announced any recent operational events (as of mid-2026). LumiThera's structural distinctiveness lies in having brought the first noninvasive, drug-free treatment for dry AMD to market in the United States. Rather than develop a pharmaceutical, it built a photobiomodulation device that can be administered in a retina specialist's office without dilation, anesthesia, or injections. The firm has not disclosed a succession plan, governance model, or any investment mandate extending beyond its core product.
General information
Firm type
other
Year founded
—
AUM
Undisclosed
Location
Region
North America
Country
United States
City
Poulsbo
Corporate office
Poulsbo, WA, United States
Additional offices
Tokyo, Japan
Sector focus
Frequently asked questions
What is Valeda and how does it differ from other dry AMD treatments?
Valeda is a medical device that delivers photobiomodulation using 590 nm, 660 nm, and 850 nm wavelengths of light to stimulate mitochondrial activity in retinal cells. It is the first FDA-authorized treatment for early and intermediate dry AMD that improves visual acuity without drugs, injections, or surgery.
What clinical evidence supports Valeda?
Valeda's FDA authorization is based on the LIGHTSITE III trial, a 24-month, double-masked, sham-controlled study of 98 patients (145 eyes). The trial found that 84% of treated patients maintained or improved vision at about two years, with more than 60% gaining at least one line of visual acuity (per the LIGHTSITE III study results published in Retina, 2024).
Who distributes Valeda commercially?
Valeda is distributed globally by Alcon, the eye care division of Novartis. Alcon markets the device through its surgical and vision care channels to retina specialists and ophthalmology practices in the United States.
Is LumiThera a family office or an investment firm?
LumiThera is a medical device company, not a family office or asset manager. It develops, manufactures, and commercializes the Valeda photobiomodulation device. No investment or wealth management activity has been disclosed.
Where is LumiThera headquartered?
LumiThera lists its headquarters in Poulsbo, Washington, with an additional office in Tokyo, Japan. The company's operational status in Japan is not publicly detailed.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on family offices?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: